
Home » BIOCRYST PHARMACEUTICALS ENTER AGREEMENT WITH GREEN CROSS TO DEVELOP AND COMMERICALIZE PERAMIVIR
BIOCRYST PHARMACEUTICALS ENTER AGREEMENT WITH GREEN CROSS TO DEVELOP AND COMMERICALIZE PERAMIVIR
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced an agreement with Green Cross Corporation, South Korea for the development and commercialization in Korea of peramivir, BioCryst's potent influenza neuraminidase inhibitor.
StreetInsider.com (http://www.streetinsider.com/news.php?id=963334&st=p)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
28Sep
-
28Sep
-
11Oct
-
16Oct
-
26Oct
-
08Nov